To confirm these findings, the antimicrobial potency of gemifloxacin was determined against a panel of recent Gram-positive and Gram-negative clinical isolates. Its potency was compared with that of trovafloxacin, grepafloxacin, levofloxacin, ciprofloxacin, ofloxacin, nalidixic acid, gentamicin, cefuroxime, penicillin, ampicillin, clarithromycin, azithromycin and trimethoprim-sulphamethoxazole. In addition, time-kill studies were performed and post-antibiotic effect (PAE) was determined to define further the potency of gemifloxacin in vitro.
Introduction
Antimicrobial resistance is an increasing problem worldwide, making many classes of antimicrobial agents less useful for therapy. 1 This loss of efficacy has driven the search for alternatives. The quinolones have proven to be a rich source of novel, highly potent, broad-spectrum agents.
Gemifloxacin (SB-265805) is a novel quinolone, currently in clinical development as an oral agent for the treatment of bacterial infections (Figure) . Previous studies have shown that gemifloxacin has effective antibacterial activity against a broad spectrum of Gram-positive and Gram-negative pathogens; its potency is similar to that of ciprofloxacin against the majority of Gram-negative organisms, but it is considerably more potent than ciprofloxacin against most Gram-positive organisms.
Materials and methods

Isolates
In all, 645 Gram-positive and 995 Gram-negative clinical isolates were tested. Most were obtained from six centres within the USA: Bryn Mawr Hospital, Bryn Mawr, PA; Stanford University Hospital, Stanford, CA; Evanston Hospital, Evanston, IL; SmithKline Beecham Clinical Laboratories (SBCL), Van Nuys, CA; SBCL, Philadelphia, PA; and SBCL, St Louis, MO. The Haemophilus influenzae isolates were obtained from the 1997 ALERT program (Laboratory Specialists Inc., Westlake, OH, USA) which was a multicentre surveillance study involving 47 US hospitals. As part of the collection process, isolates were checked for purity, their identity confirmed using a Vitek Junior (bioMérieux, Hazlewood, MI, USA) and frozen at -70°C in 10% glycerol.
Media
Trypticase soy broth containing 10% glycerol was used to freeze test isolates, and trypticase soy agar containing 5% sheep blood was used to subculture all frozen stocks, except H. influenzae, for which chocolate agar was used. Haemophilus test medium (HTM) was used for microdilution susceptibility testing of H. influenzae isolates, while cation-adjusted Mueller-Hinton broth was used for Gram-negative isolates, Staphylococcus spp. and Enterococcus spp. and (supplemented with 5% lysed horse blood) for streptococci. All media were obtained from BBL, Cockeysville, MD, USA.
Broth microdilution
Microtitre susceptibility plates prepared by Sensititre (AccuMed International Ltd, Westlake, OH, USA) were used for MIC testing. The plates contained the following antimicrobial agents in serial doubling dilutions: gemifloxacin (0.001-256 mg/L); trovafloxacin, grepafloxacin, levofloxacin, ciprofloxacin, penicillin and clarithromycin (0.016-16 mg/L); ofloxacin, nalidixic acid, gentamicin, cefuroxime, ampicillin and azithromycin (0.06-64 mg/L); and trimethoprim-sulphamethoxazole (0.06/1.14-64/1216 mg/L).
The inoculum was prepared from a single test isolate suspension to give a final inoculum density of approximately 5 ϫ 10 5 cfu/mL. 4 Each well of a Sensititre plate was inoculated with 100 L of this suspension using the Microlab AT Plus 2 (Hamilton Co., Reno, NV, USA) then covered and incubated at 35°C in ambient air for 20-24 h. Colony counts were performed on randomly selected control wells to ensure that the appropriate inoculum density had been obtained. A 10 L aliquot of the inoculum was plated to determine the purity of the final test inoculum.
MICs were defined as the lowest concentration of drug that inhibited visible growth of the test isolates. For trimethoprim-sulphamethoxazole, the MIC was defined as the concentration that produced an 80-90% decrease in growth as compared with the positive growth control. Individual MIC data were summarized as MIC range, MIC 50 and MIC 90 .
Quality control
The control organisms, included on each day of testing, were Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, Enterococcus faecalis ATCC 29212, Pseudomonas aeruginosa ATCC 27853, Streptococcus pneumoniae ATCC 49619 and E. coli ATCC 35218. Results for that day were only accepted if the quality control values were within acceptable limits, as established by the NCCLS. 5 The quality control limits tentatively approved by the NCCLS in January 1999 (Table I) were used for gemifloxacin.
Viable counts
Flasks containing 20 mL of broth were prepared for gemifloxacin and ciprofloxacin at 1, 2 and 4 ϫ MIC. A control flask without antimicrobial agent was also prepared. Each isolate was subcultured for two consecutive days and then diluted into the flasks to give a starting inoculum of approximately 1 ϫ 10 6 organisms. The flasks were placed on a shaker at 35°C. Viable counts were performed at 0, 2, 4, 6, 8 and 24 h. Up to seven 10-fold dilutions were made in the appropriate broth from each flask at each time interval. Dilutions were made in a microtitre plate using a multichannel pipette. Using a 10 L disposable loop, 5 ϫ 10 L from each well was spread on an agar plate. The plates were incubated overnight at 35°C and colony counts were determined and averaged from each sample. The limit of detection for this method was approximately 10 cfu/mL. A bactericidal effect was defined as a у3 log 10 (99.9% killing) reduction in cfu compared with the initial test inoculum. This is reported as the time taken for the initial inoculum to fall by у3 log 10 .
Post-antibiotic effect
The PAE was determined using a filtration method as previously described. 6 Each test isolate was added to a 50 mL flask containing the antimicrobial agent (at 2 or 4 ϫ MIC) in 20 mL of the appropriate broth. After addition of the isolate, a colony count was performed to determine the density (cfu/mL) of the starting inoculum. Flasks were incubated on a shaker at 35°C.
After 2 h of exposure to the antimicrobial agent, a further colony count was performed. The contents of each flask were then filtered using a 0.2 m filter to remove the antimicrobial agent. The filtrate was washed twice with 10 mL of pre-warmed broth and the filter was resuspended in 20 mL of pre-warmed medium. A colony count was performed immediately after resuspension of the test isolate. Flasks were returned to the incubator and colony counts were performed at 1 h intervals for 6 h. As it was difficult to filter the media supplements used for S. pneumoniae and H. influenzae, the inoculum was diluted 1 in 100 into pre-warmed broth to remove the antimicrobial agent in studies involving these organisms.
In PAE studies, controls included incubation of the test isolate for 2 h in drug-free medium followed by filtration and incubation of the isolate in drug-free medium. For each isolate, the number of colonies was plotted on the y-axis and time on the x-axis of a semi-logarithmic graph. The PAE was determined using the equation:
Where T is the time required for the test isolate count to increase to 10-fold (1 ϫ log 10 ) above the count observed immediately after removal of the antimicrobial agent and C is the time required for the control to increase by 10-fold above the count observed immediately after removal of the antimicrobial agent.
Results
Gemifloxacin showed a broad spectrum of antibacterial activity against a wide range of both Gram-positive (Table  I) and Gram-negative (Table II) Table III shows the time taken to reduce the viable count by 3 ϫ log 10 for a range of organisms. Both ciprofloxacin and gemifloxacin killed Gram-negative organisms more rapidly than Gram-positive organisms, with gemifloxacin usually killing organisms slightly more quickly than ciprofloxacin.
A measurable PAE was observed for both ciprofloxacin and gemifloxacin for all of the isolates tested (Table IV) . In general, the PAE at 2 ϫ MIC was shorter than that at 4 ϫ MIC. At 4 ϫ MIC, the gemifloxacin PAE was Ͼ6 h for H. influenzae, P. aeruginosa and Proteus vulgaris and ranged from 0.1 to 2.5 h for the other isolates tested. The ciprofloxacin PAEs obtained at 4 ϫ MIC ranged from 0.3 to 5.1 h.
Discussion
Gemifloxacin showed excellent activity in vitro against the majority of organisms studied although, like all other quinolones, it was less potent against enterococci, methicillin-resistant staphylococci and Gram-negative nonfermenters. These results are comparable to those of previous studies. 2, 3 Overall, MIC 90 s of gemifloxacin for Gram-positive organisms were lower than those of the comparator compounds studied. This was particularly pronounced for S. pneumoniae and the other streptococci, where MICs were four-to eight-fold lower than those of trovafloxacin, the next most potent agent.
For Gram-negative isolates, except gentamicin, the quinolones were consistently more potent than the other compounds tested. The antibacterial potency of gemifloxacin was equal to that of levofloxacin and ciprofloxacin and generally better than that of ofloxacin, grepafloxacin, trovafloxacin and nalidixic acid.
From the viable count studies reported here, it appears that the rate of kill by gemifloxacin and ciprofloxacin is greatest for the Enterobacteriaceae and P. aeruginosa, with gemifloxacin usually showing a slightly greater rate of kill than ciprofloxacin. The rate of kill for both quinolones was somewhat lower for Gram-positive organisms, where a 3 log reduction in viable count took at least 8 h. Gemifloxacin had a PAE of 0.6-2.5 h for the majority of strains tested, with even longer PAEs observed for H. influenzae, P. aeruginosa and P. vulgaris. Davies et al. reported PAEs for S. pneumoniae of 0.4-1.6 h for gemifloxacin and 0.5-1.5 h for ciprofloxacin, 7 both in broad agreement with the data reported here. For H. influenzae, 8 9 and found that gemifloxacin PAEs (2.1-4.1 h) were significantly longer than those of either ciprofloxacin (1.6-2.7 h) or trovafloxacin (1.9-3.5 h). It is likely that such discrepancies result from differences in methodology.
In conclusion, gemifloxacin is a novel quinolone with a broad spectrum of antimicrobial activity. It has substantially improved potency against Gram-positive organisms, which is most pronounced for the streptococci, where gemifloxacin is at least eight-to 16-fold more potent than the other quinolones tested. It has good Gram-negative potency, consistent with that of ciprofloxacin and levofloxacin. In addition, good bactericidal activity and demonstrable PAE indicate that gemifloxacin is among the most promising of the new quinolones. 
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